NasdaqGM:EYPTPharmaceuticals
EyePoint (EYPT) Settles DOJ Claims, Is The 71% Undervaluation Case Convincing?
EyePoint (EYPT) has entered a settlement with the U.S. Department of Justice and related agencies over past DEXYCU commercialization practices, agreeing to specified payments and a five year Corporate Integrity Agreement, without admitting liability.
See our latest analysis for EyePoint.
Set against this legal resolution, EyePoint's recent share price return has softened, with the stock down 15.52% over 30 days and 31.81% year to date. However, the 1 year total shareholder return is 21.14%,...